Division of Cardiovascular Medicine (Y.G., J.Y.S., Z.Z., Y.-J.N., T.F., H.L.), Vanderbilt University Medical Center, Nashville, TN.
Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN (Y. Guo, J.V.B.).
Circulation. 2019 Nov 26;140(22):1820-1833. doi: 10.1161/CIRCULATIONAHA.119.040740. Epub 2019 Oct 4.
Cardiac kinases play a critical role in the development of heart failure, and represent potential tractable therapeutic targets. However, only a very small fraction of the cardiac kinome has been investigated. To identify novel cardiac kinases involved in heart failure, we used an integrated transcriptomics and bioinformatics analysis and identified Homeodomain-Interacting Protein Kinase 2 (HIPK2) as a novel candidate kinase. The role of HIPK2 in cardiac biology is unknown.
We used the Expression2Kinase algorithm for the screening of kinase targets. To determine the role of HIPK2 in the heart, we generated cardiomyocyte (CM)-specific HIPK2 knockout and heterozygous mice. Heart function was examined by echocardiography, and related cellular and molecular mechanisms were examined. Adeno-associated virus serotype 9 carrying cardiac-specific constitutively active MEK1 (TnT-MEK1-CA) was administrated to rescue cardiac dysfunction in CM-HIPK2 knockout mice.
To our knowledge, this is the first study to define the role of HIPK2 in cardiac biology. Using multiple HIPK2 loss-of-function mouse models, we demonstrated that reduction of HIPK2 in CMs leads to cardiac dysfunction, suggesting a causal role in heart failure. It is important to note that cardiac dysfunction in HIPK2 knockout mice developed with advancing age, but not during development. In addition, CM-HIPK2 knockout mice and CM-HIPK2 heterozygous mice exhibited a gene dose-response relationship of CM-HIPK2 on heart function. HIPK2 expression in the heart was significantly reduced in human end-stage ischemic cardiomyopathy in comparison to nonfailing myocardium, suggesting a clinical relevance of HIPK2 in cardiac biology. In vitro studies with neonatal rat ventricular CMscorroborated the in vivo findings. Specifically, adenovirus-mediated overexpression of HIPK2 suppressed the expression of heart failure markers, and , at basal condition and abolished phenylephrine-induced pathological gene expression. An array of mechanistic studies revealed impaired extracellular signal-regulated kinase 1/2 signaling in HIPK2-deficient hearts. An in vivo rescue experiment with adeno-associated virus serotype 9 TnT-MEK1-CA nearly abolished the detrimental phenotype of knockout mice, suggesting that impaired extracellular signal-regulated kinase signaling mediated apoptosis as the key factor driving the detrimental phenotype in CM-HIPK2 knockout mice hearts.
Taken together, these findings suggest that CM-HIPK2 is required to maintain normal cardiac function via extracellular signal-regulated kinase signaling.
心脏激酶在心力衰竭的发展中起着关键作用,是潜在的可治疗靶点。然而,仅有一小部分心脏激酶组被研究过。为了鉴定参与心力衰竭的新型心脏激酶,我们采用整合转录组学和生物信息学分析,鉴定出同源结构域相互作用蛋白激酶 2(HIPK2)为一种新型候选激酶。HIPK2 在心脏生物学中的作用尚不清楚。
我们使用 Expression2Kinase 算法筛选激酶靶标。为了确定 HIPK2 在心脏中的作用,我们生成了心肌细胞(CM)特异性 HIPK2 敲除和杂合子小鼠。通过超声心动图检查心脏功能,并检测相关的细胞和分子机制。携带心脏特异性组成型激活 MEK1(TnT-MEK1-CA)的腺相关病毒血清型 9 被用来挽救 CM-HIPK2 敲除小鼠的心脏功能障碍。
据我们所知,这是首次定义 HIPK2 在心脏生物学中的作用的研究。使用多种 HIPK2 功能丧失型小鼠模型,我们证明了心肌细胞中 HIPK2 的减少会导致心脏功能障碍,提示其在心力衰竭中起因果作用。需要注意的是,HIPK2 敲除小鼠的心脏功能障碍随着年龄的增长而发展,但不是在发育过程中。此外,CM-HIPK2 敲除小鼠和 CM-HIPK2 杂合子小鼠的心脏功能与 CM-HIPK2 的基因剂量呈正相关。与非衰竭心肌相比,人类终末期缺血性心肌病患者心脏中的 HIPK2 表达明显降低,提示 HIPK2 在心脏生物学中具有临床相关性。新生大鼠心室心肌细胞的体外研究证实了体内研究结果。具体来说,腺病毒介导的 HIPK2 过表达抑制了心力衰竭标志物 和 的表达,在基础条件下和取消了去甲肾上腺素诱导的病理性基因表达。一系列机制研究表明,HIPK2 缺陷心脏中的细胞外信号调节激酶 1/2 信号受损。携带 TnT-MEK1-CA 的腺相关病毒血清型 9 的体内挽救实验几乎消除了敲除小鼠的有害表型,提示细胞外信号调节激酶信号受损介导的细胞凋亡是导致 CM-HIPK2 敲除小鼠心脏有害表型的关键因素。
综上所述,这些发现表明,CM-HIPK2 通过细胞外信号调节激酶信号维持正常心脏功能。